2023
Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites
Chin A, Bastaich D, Dahman B, Kaplan D, Taddei T, John B. Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites. Hepatology 2023, 79: 844-856. PMID: 37625139, DOI: 10.1097/hep.0000000000000577.Peer-Reviewed Original ResearchLiver-related deathRefractory hepatic hydrothoraxRefractory ascitesMELD-NaHepatic hydrothoraxHigh riskRetrospective cohort studyRA overallSecond paracentesisCohort studyPrimary outcomeSerious complicationsEligibility criteriaCirrhosisInadequate evidenceParacentesisHydrothoraxAscitesDeathPatientsTransplantationRiskMortalityParticipantsComplications
2021
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDiabetes mellitusLiver diseaseNon-alcoholic fatty liver diseaseCotransporter 2 inhibitorsChronic liver diseaseFatty liver diseaseVeterans Affairs hospitalIncidence of ascitesAdditional pharmacotherapyTreat analysisElectronic health dataSGLT2 inhibitorsSGLT2i usersSurrogate biomarkerDPP4 inhibitorsMetabolic effectsPatientsCirrhosisPropensity scoreAscitesConfirmatory studiesMetformin
2018
SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites
Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clinical Liver Disease 2018, 11: 141-144. PMID: 30992805, PMCID: PMC6385962, DOI: 10.1002/cld.714.Commentaries, Editorials and Letters
2012
Beta‐blockers in patients with refractory ascites: To treat or not to treat. That is the question? But, what is the answer?
Guevara M, Groszmann R, Iwakiri Y, Taddei T. Beta‐blockers in patients with refractory ascites: To treat or not to treat. That is the question? But, what is the answer? Hepatology 2012, 56: 384-386. PMID: 22454325, DOI: 10.1002/hep.25724.Peer-Reviewed Original ResearchParacentesis-induced circulatory dysfunctionIncidence of paracentesis-induced circulatory dysfunctionPlasma renin concentrationRefractory ascitesBeta-blockersArterial pressureDevelopment of paracentesis-induced circulatory dysfunctionHeart rateTreated with beta-blockersChild-Pugh C.Intravenous albumin administrationBeta-blocker therapyEradication of varicesCross-over studyBaseline 1 weekEndoscopic eradicationAlbumin administrationBeta blockersMELD scoreRenin concentrationCirculatory dysfunctionAscitesCirrhosisParacentesisPatients